Taxotere (chemotherapy for prostate cancer) is administered intravenously usually in an cancer center or a hospital setting. Often the areas which are designated for chemo administration are referred to as infusion centers. Taxotere is administered with either on a higher dosage schedule of once every three weeks (q3wk) or a lower dosage schedule of once [...]
The current standard of care in the treatment of prostate cancer is to use chemotherapy (Taxotere) only in late stage hormone refractory prostate cancer. Most other cancers use chemotherapy agents at a much earlier stage then used for prostate cancer. Prostate cancer cells divide at a rate that is not much faster than normal cell [...]
April 14 in the Journal of Clinical Oncology reported that Eric M. Horwitz, M.D., from Fox Chase Cancer Center in Philadelphia, and colleagues treated 1,554 prostate cancer patients with goserelin and flutamide (ADT) before and during radiation therapy. The men were then randomly assigned to receive no further ADT or 24 additional months of ADT. [...]
When I provided testimony at the FDA in support of the application for approval of the vaccine Provenge®, I had the opportunity of meeting some of the representatives of the biotech company Antigenics (AGEN). Since I am also a renal cancer survivor they initially approached me asking if I would be willing to meet them [...]
I want to apologize because I have not posted anything in the last few days. I thank the few people who sent an e-mail expressing concern. On Friday evening I flew to San Diego with my wife to participate in the American Association of Cancer Researchers (AACR) Scientist-Survivor program. It is a really fantastic program [...]
On the Prostate Problems Mailing List there has been some recent discussion and a large amount of confusion expressed about the need for and importance of surrogate end points for drug and treatment approval. I attempted to make a very simple clarification and recommendation about surrogates. Here it is, but slightly modified ……. Maybe I [...]
At the European Association of Urology’s 23rd Annual Congress there was an abstract presented (Abstract 186) that concluded that three-dimensional external beam radiation (EBRT) with 6 months of androgen deprivation therapy (ADT) for the treatment of patients with locally advanced prostate cancer shows significantly shorter patient survival than the same treatment followed by 3 years [...]
Gynecomastica is a taboo subject with many men. Men have a hard enough time talking about prostate cancer, but discussing their breast growth is just too much for many. However, many of us who are treated for prostate cancer experience breast growth, gynecomastica. Despite how difficult it is to discuss it, gynecomastica is one of [...]
A recent announcement about the once daily oral drug abiraterone acetate (CB7630) indicated that some of the current trial results demonstrate some efficacy in men with hormone refractory prostate cancer. The positive results appeared at two different stages of the standard treatment process. Positive results were demonstrated both before and after the administration of chemotherapy. [...]
Many of us think that chemotherapy for prostate cancer only involves the use of Taxotere. Just for the sake of accuracy, I want to clarify that almost every drug we take to treat prostate cancer is chemotherapy. Chemotherapy drugs are the drugs that are designed to kill cells. All of the drugs used as a [...]
